On January 16, 2025, Avacta reported encouraging results from its Phase I trial of AVA6000. In patients with salivary gland ...

Sarepta reported a quarter-on-quarter dip in sales for its Duchenne gene therapy. Elsewhere, Jazz won FDA approval of a brain cancer drug and Novo decided to advance a Prothena medicine into Phase 3.

Goldman Sachs analyst Asad Haider maintained a Hold rating on Pfizer yesterday and set a price target of $27.00. The company’s shares closed yesterday at $23.93. Take advantage of TipRanks Premium at ...